FDA clears antidepressant use of Abilify

11/20/2007 | Forbes

Bristol-Myers Squibb Co.'s schizophrenia drug Abilify has been approved by the FDA for use as an additional antidepressant treatment for people with major depressive disorder. The decision follows a clinical trial involving 743 patients. The drug is co-marketed by Otsuka Pharmaceutical Co.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care